Abstract
BackgroundWe aimed to evaluate the effects of short-term therapy with dapagliflozin on serum uric acid (SUA) and urinary uric acid (UUA) levels in patients with type 2 diabetes.MethodsIn this prospective pilot trial, 8 patients with type 2 diabetes mellitus were assigned to the treatment group with dapagliflozin 10 mg once daily for one week, and 7 subjects with normal glucose tolerance were recruited into the control group. Data of anthropometric measurements, SUA, 24-h UUA, fractional excretion of UA (FEUA), serum lipid parameters and 3-h oral glucose tolerance test (OGTT) were collected in both treatment and control groups; all examinations were repeated after treatment. The area under the curve of glucose (AUCGlu) was calculated to reflect the general glucose levels, while insulin resistance and islet β-cell function were reflected by indexes calculated according to the data obtained from the OGTT.ResultsThe weight and serum lipid parameters showed no differences before and after treatment with dapagliflozin for one week. We found SUA levels decreased from 347.75 ± 7.75 μmol/L before treatment to 273.25 ± 43.18 μmol/L after treatment, with a statistically significant difference (P = 0.001) and was accompanied by a significant increase in FEUA from 0.009 to 0.029 (P = 0.035); there was a linear correlation between SUA and FEUA levels. Glucose control, insulin sensitivity and islet β-cell function were improved to a certain extent. We also found a positive correlation between the decrease in glucose levels and the improvement in islet β-cell function.ConclusionsThe SUA-lowering effect of dapagliflozin could be driven by increasing UA excretion within one week of treatment, and a certain degree of improvement in glucose levels and islet β-cell function were observed.Trial registration ClinicalTrials.gov identifier, NCT04014192. Registered 12 July 2019, https://www.clinicaltrials.gov/ct2/show/NCT04014192:term=NCT04014192&draw=2&rank=1. Yes.
Highlights
We aimed to evaluate the effects of short-term therapy with dapagliflozin on serum uric acid (SUA) and urinary uric acid (UUA) levels in patients with type 2 diabetes
Fasting blood glucose (FBG) (P = 0.005), area under the curve of glucose (AUCGlu) (P < 0.001) in the 3-h oral glucose tolerance test (OGTT) and Glycated hemoglobin (HbA1c) (P = 0.002) were significantly higher in the treatment group compared with the control group, which was in accord with the characteristics of glucose metabolism in these two groups
Characteristics of urinary parameters At baseline, the concentration of 24-h UUA and fractional excretion of UA (FEUA) were both higher in the treatment group compared with the control group, which indicated a higher excretion of uric acid (UA) in subjects with Type 2 diabetes mellitus (T2DM)
Summary
We aimed to evaluate the effects of short-term therapy with dapagliflozin on serum uric acid (SUA) and urinary uric acid (UUA) levels in patients with type 2 diabetes. Yuan et al Diabetol Metab Syndr (2020) 12:92 to improve glycemic control and to benefit combined metabolic disorders. Under these circumstances, there are many new hypoglycemic drugs that have emerged in recent years, including sodium-glucose cotransporter-2 (SGLT2) inhibitors. SGLT2 inhibitors exert hypoglycemic effects by increasing urine glucose excretion in an insulin-independent way [2]. A variety of SGLT2 inhibitors have been marketed around the world with gradually increasing clinical application
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
